we know amgen could be a competitor.nd so this is, i guess, the crucial time when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 3035. we are perhaps serving one million or two million of those today. so, there is a huge market opportunity, and there is a place for more. and then, you're right, that in most markets when you get more competition, and also over time, pricing starts moving down, because you start treating those who accept, say, the higher price point -- in the u.s., that's commercial insurance -- and then, over time, you get broader access, and you get patients paying a lower price. so if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc. is some 40% lower than when we launched. that is often not mentioned in, say, the political

we know amgen could be a competitor.his is, i guess, the crucial time, when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 2035. we are perhaps serving one million or two million of those today. so there is a huge market of opportunity, and there is a place for more. and then, you're right. in most markets, when you get more competition, and also, over time, pricing starts moving down, because you start treating those who accept, say, the higher price point -- in the u.s., that is commercial insurance -- and over time you get broader access, and you get patients paying a lower price. if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc., is some 40% lower than when we launched. that is often not mentioned in, say, the political debate. instead

we know amgen could be a competitor.nd so this is, i guess, the crucial time when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 3035. we are perhaps serving one million or two million of those today. so, there is a huge market opportunity and there is a place for more. and then, you're right, in most markets when you get more competition, and also over time pricing starts moving down, because you start treating those who accept, say, the higher price point -- in the u.s., that is commercial insurance -- and over time you get broader access, and you get patients paying a lower price. so if you just take our leading diabetes product in the u.s., since launch in 2018 the price we get after rebates, discounts, etc., is some 40% lower than when we launched. that is often not mentioned in, say, the political debate. inste

we know amgen could be a competitor.is, i guess, the crucial time, when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 3035. we are perhaps serving one million or two million of those today. so there is a huge market of opportunity, and there is a place for more. and then, you're right. in most markets, when you get more competition, and also, over time, pricing starts moving down, because you start treating those who accept, say, the higher price point -- in the u.s., that is commercial insurance -- and over time you get broader access, and you get patients paying a lower price. if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc., is some 40% lower than when we launched. that is often not mentioned in, say, the political debate. instead, th

we know amgen could be a competitor.his is, i guess, the crucial time, when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 3035. we are perhaps serving one million or two million of those today. so there is a huge market of opportunity, and there is a place for more. and then, you're right. in most markets, when you get more competition, and also, over time, pricing starts moving down, because you start treating those who accept, say, the higher price point -- in the u.s., that is commercial insurance -- and over time you get broader access, and you get patients paying a lower price. if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc., is some 40% lower than when we launched. that is often not mentioned in, say, the political debate. instead

we know amgen could be a competitor. is, i guess, the crucial time, when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 3035. we are perhaps serving one million or two million of those today. so there is a huge market of opportunity, and there is a place for more. and then, you're right. in most markets, when you get more competition, and also, over time, pricing starts moving down, because you start treating those who accept, say, the higher price point -- in the u.s., that is commercial insurance -- and over time you get broader access, and you get patients paying a lower price. if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc., is some 40% lower than when we launched. that is often not mentioned in, say, the political debate. instead, t

we know of eli lilly, and amgen could be a competitor.nd so this is i guess a crucial time when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 3035. we are perhaps serving one or two million of those today. so there is a huge market opportunity here, and there is a place for more. and you are right. in most markets, when you get more competition and also, over time, pricing moves down, because you start treating those who accept, say, the higher price point -- in the u.s., that is commercial insurance -- and, over time, you get broader access and you get patients paying a lower price. if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc., is some 40% lower than when we launched. that is often not mentioned in, say, the political debate. instead, the list price

we know amgen could be a competitor.o this is, i guess, the crucial time when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 3035. we are perhaps serving one million or two million of those today. so, there is a huge market opportunity, and there is a place for more. and then, you're right, that in most markets when you get more competition, and also over time, pricing starts moving down, because you start treating those who accept, say, the higher price point -- in the u.s., that's commercial insurance -- and then, over time, you get broader access, and you get patients paying a lower price. so if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc. is some 40% lower than when we launched. that is often not mentioned in, say, the political deba

we know amgen could be a competitor.nd so this is, i guess, the crucial time when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 3035. we are perhaps serving one million or two million of those today. so, there is a huge market opportunity and there is a place for more. and then, you're right, in most markets when you get more competition, and also over time pricing starts moving down, because you start treating those who accept, say, the higher price point -- in the u.s., that is commercial insurance -- and then over time you get broader access, and you get patients paying a lower price. so if you just take our leading diabetes product in the u.s., since launch in 2018 the price we get after rebates, discounts, etc., is some 40% lower than when we launched. that is often not mentioned in, say, the political debate.

we know amgen could be a competitor.his is, i guess, the crucial time, when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 3035. we are perhaps serving one million or two million of those today. so there is a huge market of opportunity, and there is a place for more. and then, you're right. in most markets, when you get more competition, and also, over time, pricing starts moving down, because you start treating those who accept, say, the higher price point -- in the u.s., that is commercial insurance -- and over time to get broader access, and you get patients paying a lower price. if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc., is some 40% lower than when we launched. that is often not mentioned in, say, the political debate. instead,

and the hate merchant amgen . chaudhry could merchant amgen. chaudhry could face life behind bars as he's sentenced for directing a terrorist organisation would bnng terrorist organisation would bring you the latest on that later today. >> so a lot of crime , >> so a lot of crime, unfortunately, we're talking about this morning, but we are going to have a guest who is doing a really amazing work in his area, actually, isn't he chief constable of norfolk, who's got a zero tolerance approach to shoplifting? >> he's had remarkable results. so if he can do it, why can't other . so he's so if he can do it, why can't other. so he's coming on the program to talk to us about that. >> that's right. get in touch this morning. gbnews.com/yoursay first though, the very latest news headlines with sophia wenzler . wenzler. >> beth thank you. >> beth thank you. >> good morning. it's 931. i'm sophia wenzler in the gb newsroom. a 17 year old boy remains in custody after yesterday's knife attack in southport, in which two children were killed. six other children

followed by amgen and cisco systems. turning back to the big story of the week.e rebound in small caps and historic out performance of the s&p yesterday. look at that right now. the russell is up over 3.5% yesterday. big jump yesterday on the back of cpi. week to date up 5%. again, that softer cpi report led to a rotation. we are checking the bond market ahead of the read today which is ppi. look at yields. the benchmark at 4.22. it came down a few basis points from yesterday after that cooler than expected cpi report. something we will continue to watch throughout the show. we are looking at oil this morning adding to the week-to-date gains. wti and brent crude. wti up over .5%. crude up as well. strong week for oil overall. >>> let's see how europe is shaping up as its trading day gets under way with arasilvia ao in the london newsroom. >> good morning, frank. happy friday. we have all of the major boards trade in the green. in fact, the stoxx 600, the benchmark in europe, is trading at a month high on upbeat earnings. the cpi report we got from the united stat

let's take a look at the dow winners my eyesight will help me, boeing, merck, apple, goldman sachs, amgenw 3%, the s&p 500 winners let's take a look at the constellation energy, tesla we talked about tesla, merck, boeing and return a and the nasdaq winners, the tech heavy nasdaq if you can see constellation energy, tesla, but during a, apple ii among those up about what it half percent, coming up u.s. military bases in europe are on heightened alert for a possible terrorist attack we will have the details on that story, billionaire investor bill ackman says there's one person to blame for joe biden not stepping down, that is first lady joe biden in will bring you his full comments, and meanwhile nancy pelosi suggested the donald trump who has dementia. roll tape. >> there are healthcare professionals who think that trump has dementia, that his connection and his thoughts of not going together. ashley: doctor marc siegel will deal with that next. l♪ everywhere but the seat. the seat is leather. alan, we get it. you love your bike. we do, too. that's why we're america's number-one motorcycl

five minutes and the dow is up 139, 145 points, one third of 1%, the top winners among the dow 30 is amgenng, american express, apple and nike all up, as for the s&p 500, i cannot read that. tesla on semi and henry schein. nasdaq winners, trade dress, tesla is on the list, and z scale are all on that. the ten year treasury like e number but i think politics is kind of important, the yield is down a fraction, four-point to 2%, gold i believe this is close to a record high, there's a record 2446, i'm sure, it's down 30 cents, looking for coin 67854 as we speak, the price of oil dropping below $80, 79 - 49, nat gas below $3, 2.23, the average price for a gallon of regular is 3.50 and diesel 3.82, coming up, the democrats are in disarray, it's an absolute mess, biden and the clintons indoors, the hearers, obama ample ocr not endorsing her, will cain breaks it down. if, the becomes the democrat nominee, americans can expect more of this, roll tape. >> president biden is self isolating both medically and politically. >> is he aware the entire party is giving up on him? >> i'm sorry we ran the wr

spoke about abbvie amgen, a name i purchased recently. rates generally good for biotechs, consider the xvi, merck, mckes and pfizer above $30. josh brown is good job talking about that on "halftime." >> everything outside of lilly actually better bounce in the last week or so. what about this edwards plif sci lifesciences today? taken apart. anything to add? >> to a certain extent, i keep emphasizing positioning. that was one of the favorite names in the health care sector. regeneron and edwards lifesciences. again, working off positions here. i don't know if the business is damaged in the sense where you look at it and say, okay. we're going put this in the penalty box. you have to understand there's probably more selling pressure to come. >> speaking of stocks that have been working off maybe credit positioning. deckers. hear from them, pippa, after the close >>> yeah. deckers brands, ugg and hoka performing pretty well in recent quarters opinion the stock pulled back in the last month on worries of a slowdown in direct-to-consumer sale

the big -- amgen.der's first source, bank of new york, enfaze energy and coming up on the friday morning and food delivery fees in new york have spiked 58% in the last year and we'll tell you what caused the massive jump. hillary clinton has a message for democrats ode to oust biden and can't force them out and tomi lahren will take that one on next. ♪ when the sawdust settles and the engine roars the thing you care about is a job well done. but when you get your tools from harbor freight something about the job feels different - your wallet. whatever you do, do it for less, at harbor freight. ♪ did i read this? did i get eggs? where are my keys? memory and thinking issues keep piling up? it may be due to a buildup of amyloid plaques in the brain. visit morethannormalaging.com olukai sandals capture the feeling of stepping barefoot into wet sand. the perfect balance of instant comfort and lasting support. say aloha to olukai. anywhere comfort. anywhere aloha. (♪) it's odd how in an instant things can t

goldman, jpmorgan, travelers, amgen and unitedhealth. >>> still ahead, back in 2018 kamala harris comparedr acting i.c.e. director tom homan, or you know he's going to be fired up about that. he's on the show. >>> democrats have a new attack line calling republicans weird. you know, that could become fire. bret baier will have his stay on it. >>> -- say on it. >>> tensions amply fight in israel. are is a wider war inevitable? tennessee senator bill hagerty will answer that. >>> j.d. vance's cat lady comments not going over well. allysia finley of the "wall street journal" is not happy. she's just hate. the 10:00 hour is next. ♪ i need a hero, i'm holding out for a hero til the end of the night ♪ it's odd how in an ins .. slipping out of balance into freefall. i'm glad i found stability amidst it all. gold. standing the test of time. (marci) so, how long have you lived here? and how are the restaurants around here? are they good, bad, meh? (luke) marci, we've gotta go. (marci) i'm sorry. (luke) we've got seventeen thousand more parks to visit. [marci screams] (luke) we bring you the best ne

amgen, you've got proctor and gamble. give me a sense of what you see here.hat i described and sent to you earlier, liz, was basically those companies that i think could holdup when we go through this digestive phase. granted, we do have buy recommendations on technology issues, certainly in the semiconductor space like nvidia, like amd, et cetera, but in terms of what investors be looking to pick-up now, because i'm in agreement with brett that there could be some digestion of gains going forward , as i had mentioned, i think we're going to be going through these shake and bake process, bake based on the temperature outside, but the shake because i'm expecting another decline in excess of 5% this year, and that be obviously leading to excess volatility and it's usually the defensive areas like staples, healthcare, utilities, that tend to be the safe havens for investors, when we do go through such a shock. liz: oh, okay do you see any kind of shock like that, brent, and that said, is that what is really pushing your call to kind of cool off on some of these

at the bottom there, amgen and merck. well, saying there's the beach. beautiful picture, is it not?is the fourth, and many people will be heading to the shore. the american lifeguard association wants to make sure that people are staying safe and aware of rip currents that can be deadly. we're going to bring you all of that next. ♪ oh, sweet freedom, may you stay in our land along the way ♪ if introducing new advil targeted relief. the only topical pain reliever with 4 powerful pain-fighting ingredients that start working on contact to target tough pain at the source. for up to 8 hours of powerful relief. new advil targeted relief. ♪ ♪ ashley: tomorrow is independence day, of course. millions of people are going to be traveling to celebrate. aaa says this is going to be the busiest with fourth of july week ever. yikes. jeff flock joins me now. he's driving down the pennsylvania turnpike. do you have a lot of company there, mr. jeff? [laughter] >> reporter: we're headed for the shore, ashley. yeah, we gotta get to the jersey shore. we're just getting onto the turnpike right now, and

harmony happens to be heavily shorted as well and i show amgen because it has been in the portfolio foreverotech but i love health care right now. a lot of people got over their skis, liz, if you will, a.i., a.i., some of these drug companies will use machine learning to get more products out sooner and little guys become acquisition targets to the big ones as well. liz: they sure do. jordan, 30 seconds left, tomorrow, pce, personal consumption expenditure, the most important inflation number every month for the federal reserve. what are you expecting and can you anticipate what the fed might do? >> i think the fed is on hold right now. everyone is calling some people were saying earlier, three cuts right now. they're begging for rate cuts. be careful what you wish for. they will see it when weakness in housing, employment, muted number. i got 5%. they wish they did and wished they owned it right stocks instead. i don't think the fed is doing anything. i think the clues for the fed easing are not coming this month and next. liz: jordan kimmel. always a pleasure. [closing bell rings] there i

we talk about them, regeneron, amgen is in there. it's having a day.oney starts to flow out of the big cap tech names. one of the places it's going to wind up is in bio tech. i think you stay with that trade here. especially gilead. raymond james just put a $93 price target on it. >> there's an argument that it should get some credit for its weight loss drug. but what we saw today, going back to the top of the show, grasso, money flowing out of the most crowded trades, that's eli lilly and novo nordisk. we're seeing this within the sector a little bit here. >> yeah, those -- they really have to -- they're the nvidias, right? the -- lilly and the novo are the nvidias of the biotech space. you should see some money come out and use those as cash machines, but the problem is, they're the ones who have c cornered the market. i think it's ironic, when you look at pfizer's chart, it's given up all of the vaccine from covid benefit. so, you look at the chart, you go back five years, it's trading right around those, that march 2020 low in the stock, so, they'r

dow members are hitting all-time highs including american express, goldman sachs, jpmorgan and amgen of course as you know, goldman and jpmorgan had reported earnings tuesday and monday respectively. what about the rate cut hope trade getting a boost from an appearance by the financial markets federal reserve chair jay powell. yesterday at the d.c. economic club he gave the message the markets wanted. a rate cut will come before inflation finally drops to the fed's target rate of 2%. the last piece of this rally puzzle, the trump trade, the increasing likelihood at the moment that the former president will retake the white house in the upcoming presidential election has stocks moving higher but of all the indices, the russel unloved for so long, is far and away the biggest beneficiary of the trade as we're calling it. in the last few hours it shattered the two and a half year resistance sealing so we're bringing in the billionaire investor whose king of digging up the unloved and ignored stocks and making them mario gabelli joining us now. mario, russel up 10% over just the past five

home depot is rallying, caterpillar, amgen, and that's all part of the story. 30 minutes into the tradings of tinder parent match group in the green after activist investor starboard value built a stake of more than 6.5% in the name. got some reporting on what they're after there and i'll bring it to you in just a moment. more volatility hitting shares of trump media ticker djt, still up tunnel digits despite a fall this morning. watch the financials, bank of america, morgan stanley, charles schwab on the move after results. bank of america up 4% and brian moynihan will be with us later on this show to break down the numbers and what it says about the environment. >> busy morning with retail sales and business investors. let's get to rick santelli. hey, rick. >> good morning, carl. business investors for the month of may, expected to be up 0.5% delivered. up 0.5%. what's unique here is that's the biggest build in business inventories going back to august of '22 nearly two years. yields have moved up since the stronger than expected retail sales and revises. we have another number out july

and the hate merchant amgen . chaudhry could merchant amgen.organisation would bnng terrorist organisation would bring you the latest on that later today. >> so a lot